Oncolytics Biotech (ONCY) Investor presentation summary

Mission and platform overview

• Pelareorep is a first-in-class double-stranded RNA immunotherapeutic agent targeting gastrointestinal tumors, aiming to address significant unmet needs in oncology.

• The platform is designed to provide a tolerable immunotherapy that increases survival across multiple GI tumor types.

Mechanism of action and clinical activity

• Pelareorep is delivered intravenously, evades neutralization, and selectively infects tumor cells with RAS pathway mutations, leading to tumor cell lysis and immune activation.

• Replicates in almost all evaluated tumors, with RNA detected in tumor but not stromal cells.

• Activates and expands tumor-infiltrating lymphocyte clones, transforming cold tumors into hot, immune-responsive environments.

Safety profile

• Evaluated in over 20 studies and more than 1,200 patients, including 300+ with GI tumors.

• Most common adverse reactions are flu-like symptoms and GI symptoms, generally mild and manageable.

• No maximum tolerated dose identified; adverse events are typically short-lived and manageable with OTC medications.